New Delhi, Jul 14 (PTI) Drug firm Lupin on Friday said its unit has received approval from the US health regulator to market a medication to treat various disorders like schizophrenia.

The company's Somerset-based wholly-owned subsidiary Lupin Inc has received approval from the US Food and Drug Administration (USFDA) for Chlorpromazine Hydrochloride tablets, Lupin said in a statement.

Also Read | ISRO VSSC Recruitment 2023: Vacancy Notified For Scientist, Engineer Posts in Vikram Sarabhai Space Centre at vssc.gov.in, Know How To Apply Online.

The Mumbai-based drug maker's product is the generic version of Upsher-Smith Laboratories, LLC's product.

As per IQVIA MAT data, Chlorpromazine Hydrochloride Tablets had an estimated annual sale of USD 45 million in the US.

Also Read | Delhi Floods: ITO Intersection, Rajghat Areas Flooded Due to Rise in Water Level of River Yamuna; CM Arvind Kejriwal Directs Officials To Seek Help of Army and NDRF (Watch Video).

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)